Results 171 to 180 of about 5,996,360 (285)

Cytoreductive Radical Prostatectomy in Oligometastatic Prostate Cancer: Single-Centre Experience. [PDF]

BJUI Compass
Rouf KA, Latief A, Para SA, Mushtaq Y, Gupta S, Malik SA, Mehdi S, Hamid A.   +7 more
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Genomic and phenotypic heterogeneity in prostate cancer

Nature reviews. Urology, 2020
Michael C. Haffner, W. Zwart, M. Roudier, L. True, W. Nelson, J. Epstein, A. D. De Marzo, P. Nelson, S. Yegnasubramanian   +8 more
semanticscholar   +1 more source

Detachment‐Induced FAK‐STAT3‐NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation

Advanced Science, EarlyView.
The FAK‐STAT3‐NNMT axis drives anoikis resistance in circulating tumor cells by reprogramming fatty acid oxidation. Targeting this metabolic vulnerability suppresses metastasis, untangling a key mechanism of breast cancer progression and revealing NNMT as a promising therapeutic target.
Qingchao Tong, Yilei Ma, Yuzhen Gao, Lin Zhou, Luping Lou, Qiang Fang, Sining Fang, Ru Zhao, Jin Zeng, Jun Yang, Guoli Li, Xinyou Xie, Yanzhong Wang, Jun Zhang   +13 more
wiley   +1 more source

Prostate Cancer [PDF]

Journal of Urology, 1974
openaire   +3 more sources

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Prostate Cancer Incidence, Mortality, and Survival in Switzerland.

JAMA Netw Open
Menges D, Wildisen L, Scherer T, Tancredi S, Würnschimmel C, Sigg S, Hao S, Lippuner M, Cathomas R, Templeton AJ, Chmiel C, Rentsch CA, Eberli D, Kwiatkowski M, Mortezavi A, Chiolero A, Rohrmann S, Clements M, Staehelin K.   +18 more
europepmc   +1 more source

Prostate cancer and CAR-T therapy: a systematic review. [PDF]

BMC Cancer
Hakem Zadeh F, Shah N, Bird V.
europepmc   +1 more source

Dynamic Shifts in ER–Plasma Membrane Junctions Signaling Define Pro‐Metastatic N‐Glycosylation and Predict Prostate Cancer Progression

Advanced Science, EarlyView.
Prostate cancer remains a leading cause of male cancer death, yet screening cannot reliably identify aggressive disease, underscoring the need for tissue biomarkers. It is shown that primary tumors increase ER–plasma membrane junction signaling via STIM1/ORP5, whereas metastasis features their loss, Golgi dispersal, and rapid conversion of high‐mannose
Amanda J. Macke, Tania Kamal, Taylor E. Divita, Artem N. Pachikov, Chad A. LaGrange, Rajesh Ravichandran, Martha Morton, Robert Powers, Haowen Qiu, Jean‐Jack M. Riethoven, Colm Morrissey, Melinda Wojtkiewicz, Rebekah L. Gundry, Carol A. Casey, Armen Petrosyan   +14 more
wiley   +1 more source

Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat. [PDF]

Curr Obes Rep
Feijó M, Fonseca LRS, Kiss-Toth E, Socorro S, Correia S.   +4 more
europepmc   +1 more source